BioMarin posts Q3 EPS of $0.91, nearly doubling last year’s $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
Latest Ratings for BMRN
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Piper Sandler | Maintains | Overweight | |
Nov 2021 | Credit Suisse | Maintains | Outperform | |
Nov 2021 | Morgan Stanley | Maintains | Equal-Weight |